Primary ADT Provides No Survival Benefit in Localized Prostate Cancer — Physician’s First Watch
Primary ADT Provides No Survival Benefit in Localized Prostate Cancer
By Kelly Young
Primary androgen-deprivation therapy (ADT) does not confer a survival advantage in patients with localized prostate cancer, according to an observational study in JAMA Internal Medicine.
Researchers evaluated the survival benefit of primary ADT in nearly 67,000 Medicare patients with stage T1-T2 prostate cancer. Geographic areas in the highest tertile of primary ADT use were compared with those in the lowest tertile.
Overall, areas with high use of primary ADT did not have improved 15-year overall or prostate-cancer-specific survival rates, compared with low-use areas.
While noting the study's limitations, editorialists conclude that based on this study and previous randomized trials, "there is no compelling evidence to prescribe ADT alone for men with localized prostate cancer."